the role of the microbiome in health and disease · 2018-08-15 · 12 microbiome associations with...
TRANSCRIPT
The Role of the Microbiome in Health and Disease
Jakob Begun
Mater Hospital Brisbane
Mater Research Institute - University of Queensland
2
Disclaimers• Advisory Boards and consulting:
• Gilead, Janssen, Celgene, Takeda, Pfzier, MSD, Abbvie
• Honorarium for educational activities• Abbvie, Janssen, Shire, Takeda, Ferring, Emerge Health, Pfizer
• Industry Research grants• Abbvie, Pfizer, Ferring
3
4
But there are 100 million times as many bacteria on earth as there are
stars in the universe
5
The microbiome is hot
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
1985 1990 1995 2000 2005 2010 2015 2020
Pub Med References
6
The taxonomic tree of life
7
What is the human microbiome• Microbial community colonising humans
- over 10 trillion organisms • Majority of microbiome mass localised within
the gut ~ 2 kg
• By DNA content we are >90% microbe and <10% H. sapiens = human holobiont
• Complex interactions with the epithelium, metabolism, immune system, hormonal axes, and nervous system
• A dynamic relationship to human health
8
Studying the human microbiome
• Historically – viewed through the lens of culture dependent methods and microscopic observation
• Primarily in context of disease and identification of pathogens
• Successful approach for diagnosis and treatment
9
Culture independent investigation• Advent of next generation sequencing and bioinformatics has
revolutionised the field• 16S rRNA – allows selective identification of bacterial species
• Metagenomic approaches provide detailed views of microbial genomes
• New sequence based approaches for studying the virome and mycobiome
10
Coupling sequence with big data
DNA Library preparation
and sequencing
16S rRNA sequencing
Match OTU reads
against database
Bacterial taxonomy
Relative abundance
Gene annotationMetagenomic
sequencing
Genome assembly
Map onto database
11
A dynamic microbiome
• The microbiome is a dynamic community
• Significant impact of environmental exposures
• Significant changes with age
Ottman, N., et al., Front Cell Infect Microbiol, 2012. 2: p. 104
12
Microbiome associations with disease• Alterations in microbiome composition have been associated with
many human diseases and states of health• Metabolic disease – diabetes, heart disease
• Cancer – bowel cancer, melanoma, hepatocellular carcinoma, lung cancer
• Neurologic/psychiatric – Parkinson’s, anxiety/depression, Autism
• Inflammatory diseases – rheumatological, pulmonary, genitourinary, neurologic, autoimmune disease
• Gastrointestinal disease – irritable bowel syndrome, Coeliac disease, inflammatory bowel disease
• Focus on the gut microbiome
13
A word about the gut microbiome
• Oral cavity contains multiple distinct communities
• Upper GI tract characterized by limited diversity adapted to harsh environment (acidic, bile, digestive enzymes)
• The lower intestine is oxygen poor, nutrient rich, and neutral pH
Sartor, R.B. Gastroenterology, 2008. 134(2): p. 577-94.
14
Metabolic outputs of the microbiome
• Gut microbiota utilise insoluble fibre, mucus, and non-absorbed carbohydrates, protein and fat as energy sources
• Metabolic outputs vary as a function of the microbial composition and diet
• Produce a variety of secondary metabolites
• Metabolise drugs
15
Microbiome and obesity • Ob/Ob mice develop obesity due to a leptin mutation
• But phenotype is dependent on microbiome
• Compared to WT mice, Ob/Ob mice have lower diversity and a higher Firmicutes : Bacteroidetes ratio• Corresponds to more efficient energy utilisation
Turnbaugh, P.J., Nature, 2006. 444(7122): p. 1027-31.
16
Is human obesity transmissible?• Twins discordant for obesity
• Obese twin microbiome characterized by reduced diversity and increased firmicutes
• Effect of microbiome on germ-free mice
Turnbaugh, P.J., et al. Nature, 2009. 457(7228): p. 480-4.
Ridaura, V.K., et al. Science, 2013. 341(6150): p. 1241214.
17
Weight loss surgery and the microbiomeDoes weight loss surgery shift the microbiome?
Liou, A.P., et al. Sci Transl Med, 2013. 5(178): p. 178ra41.
18
Weight loss surgery and the microbiomeIs the post-RYGB surgery microbiome therapeutic?
Liou, A.P., et al. Sci Transl Med, 2013. 5(178): p. 178ra41.
19
Gut-Brain Axis
• Bi-directional signalling between the CNS and the gut micorbiome
• CNS → Gut• Motility, secretion, intestinal permeability
• Gut → CNS• Modulation of neurotransmitter release by
the gut and direct microbial production
• Modulation of endocrine and immune signalling
Clarke, G., et al. Mol Endocrinol, 2014. 28(8): p. 1221-38.
20
Microbiome in rodents
• Natural behaviours of mice (e.g BALB/c – impaired sociality and exaggerated caution)• Altered in the germ free state
• Can be manipulated through microbiome transfer from different strains
• Antibiotic treatment can cause behavioural changes and changes in stress hormone levels
• Probiotic studies in animals can reduce anxiety/depression• Lactobacillus rhamnosus directly stimulates vagus nerve
• Gut derived serotinin production influenced by the microbiome composition
Bruce-Keller, A.JBiol Psychiatry, 2018. 83(3): p. 214-223.
21
Microbiome - Autism Spectrum Disorder• ASD is increasing in incidence (as high as 1 in 45)
• Higher incidence in developed world
• GI symptoms are prominent in ASD individuals
• In animal models manipulation of the microbiome can result in Autism like behaviours
• In human studies the microbiome signature of ASD is distinct• Decreased Bacteroidetes/Firmicutes ratio
• Decreased SCFA production, and carbohydrate fermentation
• Confounded by diet
• Small trial with oral vancomycin and minocyclineshowed some efficacy signal
Vuong, H.E. and E.Y. Hsiao, Biol Psychiatry, 2017. 81(5): p. 411-423.
22
Microbiome - Autism Spectrum Disorder
Vuong, H.E. and E.Y. Hsiao, Biol Psychiatry, 2017. 81(5): p. 411-423.
23
Bowel cancer and the microbiome
• Colon cancer is the second most common cancer in men and women
• Lifetime risk is ~1 in 11 for men and 1 in 15 for women
• Multiple epidemiologic links including increased red meat, decreased fibre, smoking, obesity, family history etc.
• Bowel cancer location mirrors microbial density
• Patients with colorectal cancer have decreased bacterial diversity globally and within the cancers
• Multiple studies show increase in Fusobacterium and a decrease in Faecalibacterium, associated with decreased SCFA
• Streptococcus Bovis translocation is a marker of CRC
• Links between gut inflammation and tumour development• Bacterial induced inflammation increase mutation rates
24
An integrated model of carcinogenesis
Tlaskalova-Hogenova H et al. Cancer J 2014;20:217-24.
25
Dietary manipulation of microbiome to decrease CRC risk• African Americans have high incidence of CRC, while CRC
rates are low in Africa• Microbiome of African American’s is “high risk” compared to rural
South Africans
• American diet has 2-3 times more fat and animal protein than African diet, which was higher in fibre
• 2-week food exchange in subjects from each population
• 20 subjects in each group• Sigmoidoscopy at baseline and after two weeks
• Times series – microbiome, metabolomics, ImmunophenotypingO'Keefe, S.J., et al., Nat Commun, 2015. 6: p. 6342.
26
Dietary manipulation of microbiome to decrease CRC risk
O'Keefe, S.J., et al., Nat Commun, 2015. 6: p. 6342. AA on NA diet NA on AA diet
27
Microbiome and response to cancer therapy• Checkpoint inhibitors targeting CTLA-4 and PD-1/PD-1L have
emerged as an effective therapy for melanoma and other cancers
• In mice engrafted with melanoma the presence of Bifidobacterium was associated with decreased tumour growth and response to anti PD-1L treatment
Sivan, A., et al. Science, 2015. 350(6264): p. 1084-9.
28
Role of microbiome in clinical response to anti-PD-1 therapy
• Examined the microbiome of a cohort of melanoma patients receiving anti-PD-1 therapy
• Responders had higher diversity and increased relative abundance Faecalibacterium• Signal for Ruminococcaceae bacteria
Gopalakrishnan, V., et al. Science, 2018. 359(6371): p. 97-103.
29
Introduction to Inflammatory bowel diseaseIBD is a chronic relapsing, or progressive inflammatory condition of the GI tract
Ulcerative colitis
• Limited to the colon
• Continuous ulcerating inflammation from rectum proximal
Crohn’s disease
• Can occur anywhere throughout the GI tract
• Discontinuous, transmural inflammation +/- granuloma
Normal colon Ulcerative colitis Crohn’s disease
30
Worldwide burden of IBD
• Worldwide prevalence ~400/100,000 (~30M patients)• Incidence in Australia 29.3/100,000 → Approximately 85,000 patients diagnosed
with IBD• Current treatment paradigms consist primarily of immunosuppressive therapy
including potent biologic therapyNg, S.C., et al. The Lancet, 2017. 390(10114): p. 2769-2778.
Crohn’s disease incidence Ulcerative colitis incidence
31
Increasing incidence of IBD over time
Crohn’s
Disease
Ulcerative
Colitis
Talley et al. AJG 2011; 106: S2-S25
32
The current model of IBD pathogenesisMultiple hits:
• Genetics
• Dietary factors
• Environmental factors
• Microbial changes
Immune dysregulation
33
Microbial “dysbiosis” associated with IBD
Gevers et al Cell Host Micro 2014. 15: 382-392
34
Manipulation of microbiome in IBD• Antibiotics are effective in luminal and perianal Crohn’s disease
• Faecal microbiota transplantation(FMT) is effective at inducing remission in ulcerative colitis
Paramsothy S, Kamm MA, et al. The Lancet 2017
35
Role of individual bacteria in IBD
• Protective effect of bacteria - F. prausnitzii
• Produces the MAM peptide – which is NF-kB supressive
F. prau abundance post-operatively Protective effect in a mouse model
Sokol, H., et al., Proc Natl Acad Sci U S A, 2008. 105(43): p. 16731-6.
36
Microbiome as a pharma target• Historically the market has been dominated by nutraceuticals
with a paucity of clinical trials• Despite the lack of evidence, sales expected top $50B in 2020
• Evidence of FMT in C. difficile colitis is established, and IBD is growing with significant interest• Openbiome – Finch, currently conducting Phase 2 trials in C. difficile
• Janssen Microbiome Institute – targetting IBD, T2D
• Seres Therapeutics – Spore based formulation in Ph 2 trials for UC and CDI
• Rebiotix acquired by Ferring Pharmaceuticals – CDI
• Nextbiotix – Bacterial treatment for IBD (F. prau)
• FDA/EMA regulatory pathways
37
Summary
• New techniques in microbiome research have led to unprecedented detail of human microbiome composition
• Multiple associations between microbiome alterations and disease states
• Functional aspects of these changes remain relatively unexplored and are somewhat limited by existing datbases
• Microbiome state influences drug metabolism and response
• Evidence in gastrointestinal disease that targeting the microbiome can treat disease such as IBD
38